[1] |
LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong.
Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
|
[2] |
LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin.
The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
|
[3] |
ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge.
Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
|
[4] |
LIANG Hongyu, ZHANG Hailin, YIN Huanxin, CHEN Fan, LU Junlin, ZHU Caihong, HU Wei, ZHOU Renpeng.
Effects of 2-APB in skin wound healing in mice through down-regulation of TRPM7
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 747-753.
|
[5] |
MAO Shuying, JIN Wei, FU Sisi, LIU Keanqi, ZHOU Zhihao, WANG Guangji, LIANG Yan.
Oral lienal peptides improve ammonia-induced coughing and inflammation in mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 601-607.
|
[6] |
JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan.
Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631.
|
[7] |
LI Xueheng, LI Long.
Research progress on the relationship between melatonin and idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 715-720.
|
[8] |
CHANG Shufu .
Progress of medical treatment of coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
|
[9] |
CHEN Yu, GU Bing, LI Huanan.
Modulating gut miocrobiota: a new strategy in the treatment of gout
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314.
|
[10] |
CHEN Yugang, TU Yanqiong, WANG Congqing, CHEN Juan, ZHANG Bohong.
Network pharmacology and molecular docking to discuss the mechanism of Jinhutongdan prescription in the treatment of cholelithiasis and experimental verification
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1090-1098.
|
[11] |
LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei.
Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.
|
[12] |
ZHOU Shiqin, LUO Yali, ZHOU Wen, Qi Xiaofeng, XIAO Mengyong.
Molecular mechanism and treatment of pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1133-1147.
|
[13] |
WU Lin, HAO Yingxiang, ZHANG Lei, ZHANG Tianxue, GAO Mingjing, LENG Yufang.
Paricalcitol attenuates intestinal ischemia-reperfusion injury in mice through HMGB1/TLR4/NF-κB signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 1-7.
|
[14] |
YANG Hechun, SHI Daohua .
Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.
|
[15] |
WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui.
Research progress of melatonin on pulmonary hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
|